The quest for VEGF and other factors that promote tumour angiogenesis was initiated many decades ago, and a long and complicated path has led to the development of inhibitors of these molecules as ...

which is designed to target immune checkpoint inhibition and angiogenesis—or the formation of new blood vessels—as a ...

Ottimo Pharma Ltd. is equipped to file an IND and take its lead bifunctional antibody into phase II development, after closing a $140 million series A. The round will accelerate development of ...

Source: Shutterstock Researchers compared the nephrotoxicity of VEGF tyrosine kinase inhibitor (TKI) therapy alone, the combination of a VEGF TKI and an immune checkpoint inhibitor (ICI), and ICI ...

Current available therapies for eye diseases associated with abnormal retinal vascular permeability, such as age-related macular degeneration, require repeated intraocular injection. Now, Scheppke ...